Melatonin in Alzheimer's disease and other neurodegenerative disorders

Behavioral and Brain Functions

Volumn 2, Issue , 2006, Pages

  Srinivasan, V ^a   Pandi Perumal, S R ^b   Cardinali, D P ^c   Poeggeler, B ^d   Hardeland, R ^d  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INDOLEPROPIONIC ACID; KYNURAMINE; LEVODOPA; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; NEUROTROPHIN; OXIDIZING AGENT; PEROXIDASE; PLACEBO; PRESENILIN 1; PRESENILIN 2; SCAVENGER; STRESS ACTIVATED PROTEIN KINASE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL LINE; CELL SURVIVAL; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITION; CYTOSKELETON; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ELECTRON TRANSPORT; ENZYME REGULATION; HORMONE SYNTHESIS; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RESPIRATORY CHAIN; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

EID: 33745699091     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-2-15     Document Type: Review

References (343)

1. Harman D: Aging: a theory based on free radical radiation chemistry. J Gerontol 1956, 11:298-300. [PubMed Abstract] Return to citation in text: [1]
2. Vollicer L, Crino B: Involvement of free radicals in dementia of the Alzheimer's type: a hypothesis. Neurobiol Aging 1990, 11:567-571. [PubMed Abstract] Return to citation in text: [1]
3. Pappolla MA, Omar RA, Kim RS, Robakis NK: Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 1992, 140:621-628. [PubMed Abstract] Return to citation in text: [1] [2] [3]
4. Reiter RJ: Oxidative processes and antioxidative defense mechanism in the aging brain. FASEB J 1995, 9:526-533. [PubMed Abstract] Return to citation in text: [1}
5. Markesbery W: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147. [PubMed Abstract] Return to citation in text: [1] [2] [3]
6. Christen Y: Oxidative stress and Alzheimer's disease. Am J Clin Nutr 2000, 71:621S-629S. [PubMed Abstract] Return to citation in text: [1]
7. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G: Oxidative stress Alzheimer's disease. Biochim Biophys Acta 2000, 1502:139-144. [PubMed Abstract] Return to citation in text: [1]
8. Srinivasan V: Melatonin oxidative stress and neurodegenerative diseases. Indian J Exp Biol 2002, 40:668-679. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5]
9. Srinivasan V, Pandi-Perumal SR, Maestroni GJM, Esquifino AI, Hardeland Cardinali DP: Role of melatonin in neurodegenerative diseases. Neurotox Res 2005, 7:293-318. [PubMed Abstract] Return to citation in text: [1] [2] [3]
10. Subbarao KV, Richardson JS, Ang LS: Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990, 55:342-345. [PubMed Abstract] Return to citation in text: [1] [2] [3]
11. Balazs L, Leon M: Evidence of oxidative challenge in the Alzheimer's brain. Neurochem Res 1994, 19:1131-1137. [PubMed Abstract] Return to citation in text: [1]
12. 1-42 contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 2004, 14:426-432. [PubMed Abstract] Return to citation in text: [1]
13. Montine TJ, Morrow JD: Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 2005, 166:1283-1289. [PubMed Abstract] Return to citation in text: [1]
14. Pamplona R, Dalfo E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, Portero-Otin Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 2005, 280:21522-21530. [PubMed Abstract] Return to citation in text: [1] [2] [3]
15. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S. Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G: Alzheimer-specific epitopes of tau represent lipid peroxidation induced conformations. Free Radic Biol Med 2005, 38:746-754. [PubMed Abstract] Return to citation in text: [1]
16. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Akseno M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield I Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995, 65:2146-2156. [PubMed Abstract] Return to citation in text: [1]
17. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA: Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998, 18:8126-8132. [PubMed Abstract] Return to citation in text: [1] [2]
18. Smith MA, Richey Harris PL, Sayre LM, Beckman IS, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997, 17:2653-2657. [PubMed Abstract] Return to citation in text: [1]
19. Adamec E, Vonsattel JP, Nixon RA: DNA strand breaks in Alzheimer's disease. Brain Res 1999, 849:67-77. [PubMed Abstract] Return to citation in text: [1]
20. Colurso GJ, Nilson JE, Verwoort LG: Quantitative assessment of DNA fragmentation and β-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci 2003, 73:1795-1803. [PubMed Abstract] Return to citation in text: [1]
21. Markesbery WR, Carney JM: Oxidative alterations in Alzheimer's disease. Brain Pathol 1999, 9:133-146. [PubMed Abstract] Return to citation in text: [1]
22. de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR: Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 2000, 80:1323-1335. [PubMed Abstract] Return to citation in text: [1]
23. Lovell MA, Markesbery WR: Ratio of 8-hydroxyguanine in intact DNA free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 2001, 58:392-396. [PubMed Abstract] Return to citation in text: [1]
24. Shigenaga MK, Ames BN: Assays for 8-hydroxy-2′-deoxyguanosine: biomarker of an in vivo oxidative DNA damage. Free Radic Biol Med 1991, 10:211-216. [PubMed Abstract] Return to citation in text: [1]
25. Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxida in the brain of Alzheimer's disease. J Neurochem 1998, 71:2034-2040. [PubMed Abstract] Return to citation in text: [1]
26. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B: A generalised increase in protein carbonyls in the brain in Parkinson but not incidental Lewy body disease. J Neurochem 1997, 69:1326-1329. [PubMed Abstract] Return to citation in text: [1] [2]
27. Behl C, Davis JB, Lesley R, Schubert D: Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827. [PubMed Abstract] Return to citation in text: [1] [2] [3]
28. Pappolla MA, Chyan Y-J, Poeggeler B, Frangione B, Wilson G, Ghiso J, Re?? RJ: An assessment of the antioxidant antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000, 107:203-231. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
29. Pratico D, Delanty N: Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. Am J Med 2000, 109:577-585. [PubMed Abstract] Return to citation in text: [1]
30. Grundman M, Delaney P: Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002, 61:191-202. [PubMed Abstract] Return to citation in text: [1]
31. Tricoire H, Locatelli A, Chemineau P, Malpaux B: Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002, 143:84-90. [PubMed Abstract] Return to citation in text: [1] [2] [3]
32. Reiter RJ, Tan D-X: Role of CSF in the transport of melatonin. J Pineal Res 2002, 33:61. [PubMed Abstract] Return to citation in text: [1] [2]
33. Reiter RJ: Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998, 56:359-384. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5]
34. Srinivasan V: Melatonin, oxidative stress and ageing. Curr Sci 1999, 76:46-54. Return to citation in text: [1]
35. Arendt J: Melatonin, circadian rhythms and sleep. New Engl J Med 2000, 343:1114-1116. [PubMed Abstract] Return to citation in text: [1] [2]
36. Cardinali DP, Rosenstein RE, Golombek DA, Chuluyan HE, Kanterewicz B, Zar MM, Vacas MI: Melatonlin binding sites in brain: Single or multiple Adv Pineal Res 1991, 5:159-165. Return to citation in text: [1]
37. Pang SF, Brown G: Regional concentrations of melatonin in the rat brain in the light and dark period. Life Sci 1983, 33:1199-1204. [PubMed Abstract] Return to citation in text: [1]
38. Catala MD, Quay WB, Vibat CRT, Timiras PS: Hypothyroidism and rehabilitation of day and night melatonin levels in pineal, hypothalamus and serum of male rats. Neuroendocrinol Lett 1987, 9:379-388. Return to citation in text: [1]
39. Skinner DC, Malpaux B: High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 1999, 140:4399-4405. [PubMed Abstract] Return to citation in text: [1]
40. Hardeland R: Antioxidative protection by melatonin - Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27:119-130. [PubMed Abstract] Return to citation in text: [1] [2] [3] (4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29]
41. Hardeland R, Pandi-Perumal SR: Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005, 2:22. [PubMed Abstract][PubMed Central Full Text] Return to citation in text: [1] [2] [3] [4] [5] (6] [7] [8] [9] [10] [11] [12] [13]
42. Poeggeler B, Cornélissen G, Huether G, Hardeland R, Jozsa R, Zeman M, Stebelova K, Olah A, Bubenik G, Pan W, Otsuka K, Schwartzkopff O, Bakken EE, Halberg F: Chronomics affirm extending scope of lead in phase duodenal vs. pineal circadian melatonin rhythms. Biomed Pharmacother 2005, 59:S219-S223. Return to citation in text: [1]
43. Fourtillan JB, Brisson AM, Fourtillan M, Ingrand I, Decourt JP, Girault J: Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol 2001, 280:E11-E22. Return to citation in text: [1]
44. Zeitzer JM, Daniels JE, Duffy JF, Klerman EB, Shanahan TL, Dijk DJ, Czeisler CA: Do plasma melatonin concentrations decline with age? Am J Med 1999, 107:432-436. [PubMed Abstract] Return to citation in text: [1]
45. Dori D, Casale G, Solerte SB, Fioravanti M, Migliorati G, Cuzzoni G, Ferrari E: Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 1994, 21:121-126. [PubMed Abstract] Return to citation in text: [1]
46. Girotti L, Lago M, Ianovsky O, Carbajales J, Elizari MV, Brusco LI, Cardinali DP: Low urinary 6-sulphatoxymelatonin levels in patients with coronary heart disease. J Pineal Res 2000, 29:138-142. [PubMed Abstract] Return to citation in text: [1]
47. Iguchi H, Kato KI, Ibayashi H: Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982, 55:27-29. [PubMed Abstract] Return to citation in text: [1]
48. Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P: Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatoni excretion in patients with Alzheimer's disease. Chronobiol Int 2001, 18:513-524. [PubMed Abstract] Return to citation in text: [1]
49. Mishima K, Okawa M, Hozumi S, Hishikawa Y: Supplementary administration of bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 2000, 17:419-432. [PubMed Abstract] Return to citation in text: [1] [2]
50. Mishima K, Okawa M, Shimizu T, Hishikawa Y: Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 2001, 86:129-134. [PubMed Abstract] Return to citation in text: [1]
51. Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI, Cardinali DP: Lack of changes in serum prolactin, FSH, TSH and estradiol after melatonin treatment in doses that improve sleep and reduce benzodlazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 2001, 30:34-42. [PubMed Abstract] Return to citation in text: [1]
52. Reiter RJ: The melatonin rhythm: both a clock and a calendar. Experientia 1993, 49:654-664. [PubMed Abstract] Return to citation in text: [1] [2]
53. Dawson D, Armstrong SM: Chronobliotics - drugs that shift rhythms, Pharmacol Ther 1996, 69:15-36. [PubMed Abstract] Return to citation in text: [1]
54. Kunz D: Chronobiotic protocol and circadian sleep propensity index: new tools for clinical routine and research on melatonin sleep. Pharmacopsychiatry 2004, 37:139-146. [PubMed Abstract]. Return to citation in text: [1]
55. Hardeland R, Pandi-Perumal SR, Cardinali DP: Molecules in focus - Melatonin. Int J Biochem Cell Biol 2006, 38:313-316. [PubMed Abstract] Return to citation in text: [1] [2]
56. Monti JM, Alvarino F, Cardinali DP, Savio I, Pintos A: Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 1999, 28:85-98. [PubMed Abstract] Return to citation in text: [1] [2]
57. Wurtman RJ, Zhdanova I: Improvement of sleep quality by melatonin. Lancet 1995, 346:1491. [PubMed Abstract] Return to citation in text: [1]
58. Esquifino AI, Pandi-Perumal SR, Cardinali DP: Circadian organization of the immune response: A role for melatonin. Clin Appl Immunol Rev 2004, 4:423-433. Return to citation in text: [1]
59. Guerrero JM, Reiter RJ: Melatonin-immune system relationships. Curr Top Med Chem 2002, 2:167-179. [PubMed Abstract] Return to citation in text: [1] [2]
60. Blask DE, Sauer LA, Dauchy C: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002, 2:113-132. [PubMed Abstract] Return to citation in text: [1]
61. Doolen S, Krause DN, Dubocovich ML, Duckles SP: Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 1998, 345:67-69. [PubMed Abstract] Return to citation in text: [1]
62. Scheer FA, Van Montfrans GA, van Sorneren EJ, Mairuhu G, Buijs RM: Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43:192-197. [PubMed Abstract] Return to citation in text: [1]
63. Wiechmann AF: Melatonin parallels in pineal gland and retina. Exp Eye Res 1986, 42:507-527. [PubMed Abstract] Return to citation in text: [1]
64. Marchiafava PL, Longoni B: Melatonin as an antioxidant in retinal photoreceptors. J Pineal Res 1999, 26:184-189. [PubMed Abstract] Return to citation in text: [1]
65. Liang FQ, Green L, Wang C, Alssadi R, Godley BF: Melatonin protects human retinal pigment epithelial cells against oxidative stress. Exp Eye Res 2004, 78:1069-1075. [PubMed Abstract] Return to citation in text: [1]
66. Srinivasan V: The pineal gland, its physiological and pharmacological role. Ind J Physiol 1989, 33:263-272. Return to citation in text: [1]
67. Srinivasan V: Psychoactive drugs, pineal gland and affective disorders. Prog Neuropsychopharmacol Biol Psychiat 1989, 13:653-664. Return to citation in text: [1]
68. Srinivasan V: Melatonin, biological rhythm disorders and phototherapy. Ind J Physiol Pharmacol 1997, 41:309-328. Return to citation in text: [1]
69. Hardeland R, Reiter RJ, Poeggeler B, Tan D-X: The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993, 17:347-357. [PubMed Abstract] Return to citation in text: [1] [2]
70. Reiter RJ, Tan D-X, Pappolla MA: Melatonin relieves the neural oxidative burden that contributes to dementias. Ann NY Acad Sci 2004, 1035:179-196. [PubMed Abstract] Return to citation in text: [1] [2]
71. Reiter RJ, Tan D-X, Leon J, Kilic U, Kilic E: When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 2005, 230:104-117. [PubMed Abstract] Return to citation in text: [1] [2]
72. Dubocovich ML, Cardinali DP, Delagrange P, Krause DN, Sugden D, Strosberg D, Yocca F: Melatonin receptors. In The IUPHAR Compendium of Receptor Characterization and Classificat 2nd edition. Edited by: Girdlestone D. London: IUPHAR Media; 2000:271-277. Return to citation in text: [1]
73. Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994, 13:1177-1185. [PubMed Abstract] Return to citation in text: [1]
74. 1b melatonin receptor. Proc Natl Acad Sci USA 1995, 92:8734-8738. [PubMed Abstract] [PubMed Central Full Text] Return to citation in text: [1]
75. Nosjean O, Ferro M, Cogé F, Beauverger P, Henlin J-M, Lefoulon F, Fauchère J-L, Delagrange P, Canet E, Boutin JA: Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000, 275:31311-31317. [PubMed Abstract] Return to citation in text: [1]
76. Hardeland R, Coto-Montes A, Poeggeler B: Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol Int 2003, 20:921-962. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]
77. Wiesenberg I, Missbach M, Kahlen JP, Schräder M, Carlberg C: Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 a synthetic ligand. Nucleic Acids Res 1995, 23:327-333. [PubMed Abstract] [PubMed Central Full Text] Return to citation in text: [1]
78. Carlberg C: Gene regulation by melatonin. Ann NY Acad Sci 2000, 917:387-396. [PubMed Abstract] Return to citation in text: [1]
79. Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S, Honma K, Kondo T Melatonin induces γ-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999, 27:838-847. [PubMed Abstract] Return to citation in text: [1] [2]
80. 2+/calmodulin-dependent kinase II activity by melatonin. Biochim Biophys Acta 1996, 1290:191-196. [PubMed Abstract] Return to citation in text: [1]
81. Anton-Tay F, Ramirez G, Martinez I, Benitez-King G: In vitro stimulation of protein kinase C by melatonin. Neurochem Res 1998, 23:601-606. [PubMed Abstract] Return to citation in text: [1]
82. Wang J, Tung YC, Li XT, Iqbal K, Grundke-Iqbal I: Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 2001, 507:81-87. [PubMed Abstract] Return to citation in text: [1] [2]
83. Gong CX, Wang JZ, Iqbal K, Grundke-Iqbal I: Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett 2003, 340:107-110. [PubMed Abstract] Return to citation in text: [1]
84. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K: Okadaic-acid-induced inhibition of protein phosphatase 2A produ activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 2003, 163:845-858. [PubMed Abstract] Return to citation in text: [1)
85. Rahman A, Grundke-Iqbal I, Iqbal K: Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated taus is a preferred substrate of protein phosphatase-1. Neurochem Res 2005, 30:277-287. [PubMed Abstract] Return to citation in text: [1]
86. Benitez-King G, Tunez I, Bellon A, Ortiz GG, Anton-Tay F: Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 2003, 182:151-159. [PubMed Abstract] Return to citation in text: [1] [2] [3]
87. Wang YP, Li XT, Liu SJ, Zhou XW, Wang XC, Wang JZ: Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions. Acta Pharmacol Sin 2004, 25:276-280. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
88. Montilla-López P, Muñoz-Águeda MC, Feijóo López M, Muñoz-Castañeda: Bujalance-Arenas I, Túnez-Fiñana I: Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cell. Eur J Pharmacol 2002, 451:237-243. [PubMed Abstract] Return to citation in text: [1]
89. Montilla P, Feijóo M, Muñoz MC, Muñoz-Castañeda JR, Bujalance I, Túnez Effect of melatonin on the oxidative stress in N1E-115 cells is not mediated by mt1 receptors. J Physiol Biochem 2003, 59:263-268. [PubMed Abstract] Return to citation in text: [1]
90. Macías M, Escames G, Leon J, Coto A, Sbihi Y, Osuna A, Acuña-Castrovie D: Calreticulin-melatonin. An unexpected relationship. Eur J Biochem 2003, 270:832-840. [PubMed Abstract] Return to citation in text: [1]
91. Pappolla MA, Simovich MJ, Bryant-Thomas YJ, Chyan YJ, Poeggeler B, Dubocovich M, Bick R, Perry G, Cruz-Sanchez F, Smith MA: The neuroprotective activities of melatonin against the Alzheimer β protein are not mediated by melatonin membrane receptors. J Pineal Res 2002, 32:135-142. [PubMed Abstract) Return to citation in text: [1] [2] [3] [4] [5] [6]
92. Selkoe DJ: Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's disease. Nat Cell Biol 2004, 6:1054-1061. [PubMed Abstract] Return to citation in text: [1]
93. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M: Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 2004, 28:67-78. [PubMed Abstract] Return to citation in text: [1]
94. Brandt R, Leschik J: Functional interactions of tau and their relevan for Alzheimer's disease. Curr Alzheimer Res 2004, 1:255-269. (PubMed Abstract] Return to citation in text: [1] [2]
95. Chong ZZ, Li F, Maiese K: Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Rev 2005, 49:1-21. [PubMed Abstract] Return to citation in text: [1]
96. Gandy S: The role of cerebral amyloid-β accumulation in common forms of Alzheimer disease. J Clin Invest 2005, 115:1121-1129. [PubMed Abstract] [PubMed Central Text] Return to citation in text: [1]
97. St George-Hyslop PH, Petit A: Molecular biology and genetics of Alzheimer's disease. C R Biol 2005, 328:119-130. [PubMed Abstract] Return to citation in text: [1]
98. Iqbal K, Grundke-Iqbal I: Metabolic/signal transduction hypothesis Alzheimer's disease and other tauopathies. Acta Neuropathol (Berl) 2005, 109:25-31. [PubMed Abstract] Return to citation in text: [1] [2]
99. Clapp-Lilly KL, Smith MA, Perry G, Duffy LK: Melatonin reduces interleukin secretion in amyloid-β stressed mouse brain slices. Chem Biol Interact 2001, 134:101-107. [PubMed Abstract] Return to citation in text: [1]
100. Lim J, Lu KP: Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 2005, 1739:311-322. [PubMed Abstract] Return to citation in text: [1]
101. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW: Tau, tang and Alzheimer's disease. Biochim Biophys Acta 2005, 1739:216-223. (PubMed Abstract] Return to citation in text: [1]
102. Brandt R, Hundelt M, Shahani N: Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta 2005, 1739:331-354. [PubMed Abstract] Return to citation in text: [1]
103. LaFerla FM, Oddo S: Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol Med 2005, 11:170-176. [PubMed Abstract] Return to citation in text: [1]
104. Behl C, Davis JB, Klier FG, Schubert D: Amyloid β peptide induces necrosis rather than apoptosis. Brain Res 1994, 645:253-264. [PubMed Abstract] Return to citation in text: [1]
105. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd I Butterfield DA: A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:3270-3274. [PubMed Abstract] [PubMed Central Full Text] Return to citation in text: [1]
106. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P: Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998, l52:871-877. [PubMed Abstract] Return to citation in text: [1] [2]
107. Connor B, Young D, Lawlor P, Gai W, Waldvogel H, Faull RL, Dragunow M Trk receptor alterations in Alzheimer's disease. Mol Brain Res 1996, 42:1-17. [PubMed Abstract] Return to citation in text: [1]
108. Hock C, Heese K, Müller-Spahn F, Hulette C, Rosenberg C, Otten U: Decreased trk A neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 1998, 241:151-154. [PubMed Abstract] Return to citation in text: (1]
109. Olivieri G, Otten U, Meier F, Baysang G, Dimitriades-Schmutz B, Müller-Spahn F, Savaskan E: β-Amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience 2003, 120:659-665. [PubMed Abstract] Return to citation in text: [1] [2]
110. Rylett RJ, Williams LR: Role of neurotrophins in cholinergic neurone function in the adult and aged CNS. Trends Neurosci 1994, 17:486-490. [PubMed Abstract] Return to citation in text: [1]
111. Finch CE, Sapolsky RM: The evolution of Alzheimer disease, the reproductive schedule and apoE isoforms. Neurobiol Aging 1999, 20:427-428. Return to citation in text: [1]
112. Smith MA, Sayre LM, Monnier VM: Radical AGEing in Alzheimer's disease. Trends Neurosci 1995, 18:172-176. [PubMed Abstract] Return to citation in text: [1]
113. Mecocci P, MacGarvey U, Beal MF: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurobiol 1994, 36:747-751. Return to citation in text: [1]
114. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler Maggio JE, Mantyh PW: Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998, 18:2161-2173. [PubMed Abstract] Return to citation in text: [1]
115. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM: Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997, 94:5296-5301. [PubMed Abstract] [PubMed Central Full Text] Return to citation in text: [1]
116. Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D: Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid β-peptide. Biochim Biophys Acta 2000, 1502:145-157. [PubMed Abstract] Return to citation in text: [1]
117. Walker DG, Lue LF, Beach TG: Increased expression of the urokinasi plasminogen-activator receptor in amyloid β peptide-treated hum brain microglia and in AD brains. Brain Res 2002, 926:69-79. [PubMed Abstract] Return to citation in text: [1]
118. Perini G, Della-Bianca V, Politi V, Delia Valle G, Dal-Pra I, Rossi F, Armato U: Role of p75 neurotrophin receptor in the neurotoxicity by β-amyloid peptidase and synergistic effect of inflammatory cytokines. J Exp Med 2002, 195:907-918. [PubMed Abstract] Return to citation in text: [1]
119. Takuma K, Yan SS, Stern DM, Yamada K: Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 2005, 97:312-316. [PubMed Abstract] Return to citation in text: [1]
120. Cardoso SM, Santos S, Swerdlow RH, Oliveira CR: Functional mitochondria are required for amyloid β-mediated neurotoxicity, FASEB J 2001, 15:1439-1441. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
121. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR: Mitochondria dysfunction of Alzheimer's disease cybrids enhances β toxicity. J Neurochem 2004, 89:1417-1426. [PubMed Abstract] Return to citation in text: [1]
122. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, Tuttle JB: Calcium homeostasis and reactive oxygen species production cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 1997, 17:4612-4622. [PubMed Abstract] Return to citation in text: [1] [2] [3]
123. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett Jr, Davis RE, Parker WD Jr: Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997, 49:918-925. [PubMed Abstract] Return to citation in text: [1]
124. Beal MF: Mitochondrial dysfunction in neurodegenerative diseases Biochim Biophys Acta 1998, 1366:211-223. [PubMed Abstract] Return to citation in text: [1] [2]
125. Beal MF: Oxidative metabolism. Ann NY Acad Sci 2000, 924:164-169. [PubMed Abstract] Return to citation in text: [1] (2]
126. Trimmer PA, Keeney PM, Borland MK, Simon FA, Almeida J, Swerdlow RH Parks JP, Parker WD Jr, Bennett JP Jr: Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol Dis 2004, 15:29-39. [PubMed Abstract] Return to citation in text: [1]
127. 2+ exchange are reduced in Alzheimer's disease cybrids. Mitochondrion 2005, 5:109-119. [PubMed Abstract] Return to citation in text: [1]
128. Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD Jr, Davis RE Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci 1999, 893:176-191. [PubMed Abstract] Return to citation in text: [1] [2]
129. Onyango IG, Bennett JP Jr, Tuttle JB: Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol Dis 2005, 19:312-322. [PubMed Abstract] Return to citation in text: [1]
130. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimme PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD Jr, Bennetl Jr: Alzheimer's disease cybrids replicate β-amyloid abnormalities through cell death pathways. Ann Neurol 2000, 48:148-155. [PubMed Abstract] Return to citation in text: [1]
131. Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP Jr, Miller SW, Davis RE, Parker WD Jr: Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 2000, 162:37-50. [PubMed Abstract] Return to citation in text: [1] [2]
132. Emerit J, Edeas M, Bricaire F: Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004, 58:39-46. [PubMed Abstract] Return to citation in text: [1]
133. Galbusera C, Facheris M, Magni F, Galimberti G, Sala G, Tremolada L, Isella V, Guerini FR, Appollonio I, Galli-Kienle M, Ferrarese C: Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients. Curr Alzheimer Res 2004, 1:103-109. [PubMed Abstract] Return to citation in text: [1]
134. Kontush K, Schekatolina S: Vitamin E in neurodegenerative disorder Alzheimer's disease: Alzheimer's disease. Ann NY Acad Sci 2004, 1031:249-262. [PubMed Abstract] Return to citation in text: (1)
135. Grundman M, Grundman M, Delaney P: Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002, 61:191-202. [PubMed Abstract] Return to citation in text: [1]
136. Luchsinger JA, Tang MX, Shea S, Mayeux R: Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003, 60:203-208. [PubMed Abstract] Return to citation in text: [1]
137. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz Norton MC, Welsh-Bohmer KA, Breitner JC, Cache County Study Group: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004, 61:82-88. [PubMed Abstract] Return to citation in text: [1]
138. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ: Midlife dietary int of antioxidants and risk of late-life incident dementia: the Honululu Asia Aging Study. Am J Epidemiol 2004, 159:959-967. [PubMed Abstract] Return to citation in text: [1]
139. 25-35 peptide-mediate neurotoxicity in rat hippocampal cultures. J Neurosci Res 1994, 39:494-505. [PubMed Abstract] Return to citation in text: [1]
140. Poeggeler B, Miravalle L, Zagorski MG, Wisniewski T, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA: Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide. Biochemistry 2001, 40:14995-15001. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5]
141. Stanyer L, Betteridge DJ, Smith CC: An investigation into the mechanisms mediating plasma lipoprotein-potentiated β-amyloid fibrillogenesis. FEBS Lett 2002, 518:72-78. [PubMed Abstract] Return to citation in text: [1]
142. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappo MA: Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol J Biol Chem 1999, 274:21937-21942. [PubMed Abstract] Return to citation in text: [1] [2] [3]
143. Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J, LeDoux SP, Wilso GL: Alzheimer β protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J Pineal Res 1999, 27:226-229. [PubMed Abstract] Return to citation in text: [1] [2]
144. Cheng X, van Breemen RB: Mass spectrometry-based screening for inhibitors of β-amylold protein aggregation. Anal Chem 2005, 77:7012-7015. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
145. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003, 85:1101-1108. [PubMed Abstract] Return to citation in text: [1] (2]
146. Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C, Zhang JT: Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004, 37:129-136. [PubMed Abstract] Return to citation in text: [1] [2]
147. Beal MF: Mitochondria, free radicals and neurodegeneration. Curr Opin Neurol 1996, 6:661-666. Return to citation in text: [1]
148. Urano S, Sato Y, Otonari T, Makabe S, Suzuki S, Ogata M, Endo T: Agin and oxidative stress in neurodegeneration. BioFactors 1998, 7:103-112. [PubMed Abstract] Return to citation in text: [1]
149. 4-Isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999, 72:734-740. [PubMed Abstract] Return to citation in text: [1]
150. Reiter RJ: Melatonin, active oxygen species and neurological dama ge Drug News Perspect 1998, 11:291-296. [PubMed Abstract] Return to citation in text: [1]
151. Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ: Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 2005, 26:519-526. [PubMed Abstract] Return to citation in text: [1]
152. Halliwell B: Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson' disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl 1989, 126:23-33. [PubMed Abstract] Return to citation in text: [1]
153. Lopez-Burillo S, Tan D-X, Mayo JC, Sainz RM, Manchester LC, Reiter RJ: Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and α lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions J Pineal Res 2003, 34:269-277. [PubMed Abstract] Return to citation in text: [1]
154. Karbownik M, Lewinski A: Melatonin reduces Fenton reaction-induce lipid peroxidation in porcine thyroid tissue. J Cell Biochem 2003, 90:806-811. [PubMed Abstract] Return to citation in text: [1]
155. Valko M, Morris H, Cronin MT: Metals, toxicity and oxidative stress. Curr Med Chem 2005, 12:1161-1208. [PubMed Abstract] Return to citation in text: [1]
156. Tan D-X, Chen L-D, Poeggeler B, Manchester LC, Reiter RJ: Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr J 1993, 1:57-60. Return to citation in text: [1]
157. Poeggeler B, Saarela S, Reiter RJ, Tan D-X, Chen L-D, Manchester LC, Barlow-Walden LR: Melatonin - a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole assessed in vitro. Ann NY Acad Sci 1994, 738:419-420. [PubMed Abstract] Return to citation in text: [1]
158. Poeggeler B, Reiter RJ, Hardeland R, Sewerynek E, Melchiorri D, Barlow-Walden LR: Melatonin, a mediator of electron transfer and repair reactions, acts synergistically with the chain-breaking antioxidants ascorbate, trollox and glutathione. Neuroendocrinol Lett 1995, 17:87-92. Return to citation in text: [1] [2]
159. Poeggeler B, Reiter RJ, Hardeland R, Tan D-X, Barlow-Walden LR: Melatonin and structurally related endogenous indoles act as potent electron donors and radical scavengers in vitro. Redox Rep 1996, 2:179-184. Return to citation in text: [1]
160. Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chl J, Ortiz GG, Acuña-Castroviejo D: A review of the evidence supportin melatonin's role as an antioxidant. J Pineal Res 1995, 18:1-11. [PubMed Abstract] Return to citation in text: [1] [2]
161. Reiter RJ, Tan D-X, Mayo JC, Sainz RM, Leon J, Czarnocki Z: Melatonin an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003, 50:1129-1146. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
162. Hardeland R, Fuhrberg B: Ubiquitous melatonin - Presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol 1996, 2:25-45. Return to citation in text: [1]
163. Hardeland R, Poeggeler B, Niebergall R, Zelosko V: Oxidation of melatonin by carbonate radicals and chemiluminescence emitted during pyrrole ring cleavage. J Pineal Res 2003, 34:17-25. [PubMed Abstract] Return to citation in text: [1]
164. 2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001, 15:2294-2296. [PubMed Abstract] Return to citation in text: [1] [2]
165. Tan D-X, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R: Chemical and physical properties a potential mechanisms: melatonin as a broad spectrum antioxidan and free radical scavenger. Curr Top Med Chem 2002, 2:181-197. [PubMed Abstract] Return to citation in text: [1] [2]
166. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003, 8:205-213. [PubMed Abstract] Return to citation in text: [1] [2]
167. Behrends A, Hardeland R, Ness H, Grube S, Poeggeler B, Haldar C: Photocatalytic actions of the pesticide metabolite 2-hydroxyquinoxaline: destruction of antioxidant vitamines and biogenic amines - implications of organic redox cycling. Redox Rep 2004, 9:279-288. [PubMed Abstract) Return to citation in text: [1] [2]
168. 1-acetyl-5-methoxykynuramine) with reactive nitrogen species Formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J Pineal Res 2005, 93:251-260. Return to citation in text: [1] [2]
169. Gitto E, Tan D-X, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, Fulia F, Barberi I: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 2001, 53:1393-1401. [PubMed Abstract] Return to citation in text: [1]
170. Tan D-X, Hardeland R, Manchester LC, Poeggeler B, Lopez-Burillo S, May JC, Sainz RM, Reiter RJ: Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions the ABTS cation radical. J Pineal Res 2003, 34:249-259. [PubMed Abstract] Return to citation in text: [1]
171. Balkan J, Sener G, Cevikbas U, Keyer-Uysal M, Uysal M: Melatonin improved the disturbances in hepatic prooxidant and antioxidant balance and hepatotoxicity induced by a cholesterol diet in C57BL mice. Int J Vitam Nutr Res 2004, 74:349-254. [PubMed Abstract] Return to citation in text: [1]
172. Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Cher LD, Poeggeler B: Melatonin stimulates brain glutathione peroxidas activity. Neurochem Int 1995, 26:497-502. [PubMed Abstract] Return to citation in text: [1]
173. Reiter RJ, Tan D-X, Osuna C, Gitto E: Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000, 7:444-458. [PubMed Abstract] Return to citation in text: [1]
174. Pablos MI, Guerrero JM, Ortiz GG, Agapito MT, Reiter RJ: Both melatonin and a putative nuclear receptor agonist CGP 52608 stimulate glutathione peroxidase and glutathione reductase activities in mouse brain in vivo. Nuroendocrinol Lett 1997, 18:49-58. Return to citation in text: [1]
175. Pablos MI, Reiter RJ, Ortiz GG, Guerrero JM, Agapito MT, Chuang JI, Sewerynek E: Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 1998, 32:69-75. [PubMed Abstract] Return to citation in text: [1]
176. Reiter RJ, Garcia JJ, Pie J: Oxidative toxicity in models of neurodegeneration: responses to melatonin. Restor Neurol Neurosci 1998, 12:135-142. [PubMed Abstract] Return to citation in text: [1] [2] [3]
177. Reiter RJ, Acuña-Castroviejo D, Tan D-X, Burkhardt S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann NY Acad Sci 2001, 939:200-215. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
178. Agapito MT, Redondo I, Plaza R, Lopez-Burillo S, Recio JM, Pablos MI: Relationships between melatonin, glutathione peroxidase, glutathione reductase, and catalase. Endogenous rhythms on cerebral cortex in Gallus domesticus. Adv Exp Med Biol 1999, 460:377-381. [PubMed Abstract) Return to citation in text: [1]
179. Pozo D, Reiter RJ, Calvo JR, Guerrero JM: Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci 1994, 55:PL455-PL460. [PubMed Abstract] Return to citation in text: [1]
180. Pozo D, Reiter RJ, Calvo JR, Guerrero JM: Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997, 65:430-442. [PubMed Abstract] Return to citation in text: [1]
181. Bettahi I, Pozo D, Osuna C, Reiter RJ, Acuña-Castroviejo D, Guerrero JM: Melatonin reduces nitric oxide synthase activity in rat hypothalamus J Pineal Res 1996, 20:205-210. [PubMed Abstract] Return to citation in text: [1]
182. Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL, Szabo C: Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibitions of NFêB activation. FASEB J 1998, 12:685-693. [PubMed Abstract] Return to citation in text: [1]
183. Chang HM, Ling EA, Chen CF, Lue H, Wen CY, Shieh JY: Melatonin attenuates the neuronal NADPH-d/NOS expression in the nodose ganglion of acute hypoxic rats. J Pineal Res 2002, 32:65-73. [PubMed Abstract] Return to citation in text: [1]
184. Rogério F, de Souza Queiroz L, Teixeira SA, Oliveira AL, de Nucci G, Langone F: F: Neuroprotective action of melatonlin on neonatal rat motoneur after sciatic nerve transection. Brain Res 2002, 926:33-41. [PubMed Abstract] Return to citation in text: [1]
185. Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V. Allescher HD: Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 2002, 33:101-108. [PubMed Abstract] Return to citation in text: [1]
186. Mayo JC, Sainz RM, Tan D-X, Hardeland R, Leon J, Rodriguez C, Reiter R.J: Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5 methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005, 165:139-149. [PubMed Abstract] Return to citation in text: [1]
187. Kelly RW, Amato F, Seamark RF: N-Acetyl-5-methoxy kynurenamine, a brain metabolite of melatonlin, is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun 1984, 121:372-379. [PubMed Abstract] Return to citation in text: [1]
188. Lapin IP, Mirzaev SM, Ryzow IV, Oxenkrug GF: Anticonvulsant activity melatonin against seizures induced by quinolinate, kainate, glutamate, NMDA, and pentylenetetrazole in mice. J Pineal Res 1998, 24:215-218. [PubMed Abstract] Return to citation in text: [1]
189. Lenaz G: The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 2001, 52:159-164. [PubMed Abstract] Return to citation in text: [1] [2]
190. Barja G, Herrero A: Localization at complex I and mechanism of the higher free radical production of brain nonsynaptic mitochondria the short-lived rat than in the longevous pigeon. J Bioenerg Biomembr 1998, 30:235-243. (PubMed Abstract] Return to citation in text: [1] [2]
191. Miwa S, Brand MD: The topology of superoxide production by comp III and glycerol 3-phosphate dehydrogenase in Drosophila mitochondria. Biochim Biophys Acta 2005, 1709:214-219. [PubMed Abstract] Return to citation in text: [1]
192. Genova ML, Ventura B, Giuliano G, Bovina C, Formiggini G, Parenti Caste G, Lenaz G: The site of production of superoxide radical in mitochondrial complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2. FEBS Lett 2001, 505:364-368. [PubMed Abstract] Return to citation in text: [1]
193. Genova ML, Merlo Pich M, Biondi A, Bernacchia A, Falasca A, Bovina C, Formiggini G, Parenti Castelli G, Lenaz G: Mitochondrial production of oxygen radical species and the role of coenzyme Q as an antioxidant. Exp Biol Med (Maywood) 2003, 228:506-513. [PubMed Abstract] Return to citation in text: [1]
194. Genova ML, Merlo Pich M, Bernacchia A, Bianchi C, Biondi A, Bovina C, Falasca AI, Formiggini G, Parenti Castelli G, Lenaz G: The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann NY Acad Sci 2004, 1011:86-100. [PubMed Abstract] Return to citation in text: [1]
195. 2 in mitochondria. J Biol Chem 2003, 278:2356-2360. [PubMed Abstract] Return to citation in text: [1] [2]
196. Xu J-X: Radical metabolism is partner to energy metabolism in mitochondria. Ann NY Acad Sci 2004, 1011:57-60. [PubMed Abstract] Return to citation in text: [1] [2]
197. Fridovich I: Superoxide radical and superoxide dismutases. Annu Rev Biochem 1995, 64:97-112. [PubMed Abstract] Return to citation in text: [1]
198. Squadrito GL, Pryor WA: Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 1998, 25:392-403. [PubMed Abstract] Return to citation in text: [1] [2]
199. Raha S, Robinson BH: Mitochondria, oxygen free radicals, disease a ageing. Trends Biochem, Sci 2000, 25:502-508. [PubMed Abstract] Return to citation in text: [1]
200. Kim JS, He L, Lemasters JJ: Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003, 304:463-470. [PubMed Abstract] Return to citation in text: [1]
201. Acuña-Castroviejo D, Martin M, Macias M, Escames G, Leon J, Khaldy H, Reiter RJ: Melatonin, mitochondria and cellular bioenergetics. J Pineal Res 2001, 30:65-74. [PubMed Abstract] Return to citation in text: [1] [2]
202. Acuña-Castroviejo D, Escames G, Carazo A, Leon J, Khaldy H, Reiter RJ: Melatonin mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem 2002, 2:133-151. [PubMed Abstract] Return to citation in text: [1] [2]
203. Acuña-Castroviejo D, Escames G, León J, Carazo A, Khaldy H: Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003, 527:549-557. [PubMed Abstract] Return to citation in text: [1] [2] [3]
204. Martin M, Macias M, Escames G, Leon J, Acuña-Castroviejo D: Melatonin but not vitamins C and E maintains glutathione homeostasis in tbutyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000, 14:1677-1679. [PubMed Abstract] Return to citation in text: [1] [2] [3]
205. Martin M, Macias M, Escames G, Reiter RJ, Agapito MT, Ortiz GG, Acuña-Castroviejo D: Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000, 28:242-248. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5]
206. Reyes-Toso CF, Ricci CR, de Mignone IR, Reyes P, Linares LM, Albornoz LE, Cardinali DP, Zaninovich A: In vitro effect of melatonin on oxygen consumption in liver mitochondria of rats. Neuroendocrinol Lett 2003, 24:341-344. [PubMed Abstract] Return to citation in text: [1]
207. Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, D-X: Nuclear localization of melatonin in different mammalian species: immunocytochemical and radioimmunoassay evidence. J Cell Biochem 1993, 53:373-382. [PubMed Abstract] Return to citation in text: [1]
208. Garcia JJ, Reiter RJ, Pie J, Ortiz GG, Cabrera J, Sainz RM, Acuña-Castrovi D: Role of pinoline and melatonin in stabilizing hepatic microsomal membranes against oxidative stress. J Bioenerg Biomembr 1999, 31:609-616. [PubMed Abstract] Return to citation in text: [1]
209. 125I]Iodomelatonin-binding sites in the pigeon brain: binding characteristics, regional distribution and diurnal variation. J Endocrinol 1991, 128:475-482. [PubMed Abstract] Return to citation in text: [1]
210. Martin M, Macias M, Leon J, Escames G, Khaldy H, Acuña-Castroviejo D: Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002, 34:348-357. [PubMed Abstract] Return to citation in text: [1] [2]
211. Okatani Y, Wakatsuki A, Reiter RJ: Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerate mice. J Pineal Res 2002, 32:143-148. [PubMed Abstract] Return to citation in text: [1]
212. Okatani Y, Wakatsuki A, Reiter RJ, Miyahara Y: Hepatic mitochondrial dysfunction in senescence-accelerated mice: correction by longterm, orally administered physiological levels of melatonin. J Pineal Res 2002, 33:127-133. (PubMed Abstract] Return to citation in text: [1]
213. Okatani Y, Wakatsuki A, Reiter RJ, Miyahara Y: Acutely administered melatonin restores hepatic mitochondrial physiology in old mice. Int J Biochem Cell Biol 2003, 35:367-375. [PubMed Abstract] Return to citation in text: [1]
214. Jou M-J, Peng T-I, Reiter RJ, Jou SB, Wu HY, Wen ST: Visualization of antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004, 37:55-70. [PubMed Abstract] Return to citation in text: [1] [2]
215. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF: Direct inhibition of mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004, 18:869-871. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4]
216. Xu M, Ashraf M: Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential. J Mol Cell Cardiol 2002, 34:75-79. [PubMed Abstract] Return to citation in text: [1]
217. Poeggeler B: Neuroprotection by indole and nitrone compounds acting as mitochondrial metabolism modifiers with potent antioxidant activity. Neurobiol Aging 2004, 25(Suppl 2):S587-S588. Return to citation in text: [1] [2] [3] (4] [5] [6] (7]
218. Bozner P, Grishko V, LeDoux SP, Wilson GL, Chyan YC, Pappolla MA: The amyloid β protein induces oxidative damage of mitochondrial DNA J Neuropathol Exp Neurol 1997, 56:1356-1362. [PubMed Abstract] Return to citation in text: [1] [2]
219. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP: Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997, 17:1046-1054. [PubMed Abstract] Return to citation in text: [1]
220. 40-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the 1 of Cu,Zn and MnSOD mRNA. J Mol Neurosci 1998, 10:181-192. [PubMed Abstract] Return to citation in text: [1]
221. Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, Bredesen DE, Hutchins JB, Hensley K, Mattson MP: Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid β-peptide. J Neurochem 1998, 70:31-39. [PubMed Abstract] Return to citation in text: [1]
222. Pereira C, Santos MS, Oliveira C: Mitochondrial function impairment induced by amyloid β-peptide on PC12 cells. Neuroreport 1998, 9:1749-1755. [PubMed Abstract] Return to citation in text: [1]
223. Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ: Amylc β-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 2001, 281:468-474. [PubMed Abstract] Return to citation in text: (1]
224. Kuperstein F, Yavin E: ERK activation and nuclear translocation in amyloid-β peptide- and iron-stressed neuronal cell cultures. Eur J Neurosci 2002, 16:44-54. [PubMed Abstract] Return to citation in text: [1]
225. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997, 17:1683-1690. [PubMed Abstract] Return to citation in text: [1] [2] [3]
226. Pappolla MA, Chyan Y-J, Bozner P, Soto C, Reiter RJ, Brewer G, Robakis N.K. Zagorski MG, Frangione B, Ghiso J: Dual anti-amyloidogenic and antioxidant properties of melatonin. A new therapy for Alzheimer disease. In Research Advance in Alzheimer's Disease. Edited by: Iqbal K, Mortimer J, Winblad B, Wisniewski HM. New York: Wiley; 1999:661-669. Return to citation in text: [1]
227. Feng Z, Zhang JT: Protective effect of melatonin on β-amyloid indu apoptosis in rat astrogiloma C6 cells and its mechanism. Free Radic Biol Med 2004, 37:1790-1801. [PubMed Abstract] Return to citation in text: [1]
228. Malchiodi-Albedi F, Domenici MR, Paradisi S, Bernardo A, Ajmone-Cat MA Minghetti L: Astrocytes contribute to neuronal impairment in Aβ toxicity increasing apoptosis in rat hippocampal neurons. Glia 2001, 34:68-72. [PubMed Abstract] Return to citation in text: [1] [2]
229. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangion B, Ghiso J: Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998, 273:7185-7188. [PubMed Abstract] Return to citation in text: [1] [2]
230. Poeggeler B, Pappolla MA, Hardeland R, Rassoulpour A, Hodgkins PS, Guidetti P, Schwarcz R: Indole-3-propionate: a potent hydroxyl radi scavenger in rat brain. Brain Res 1999, 81S:382-328. [PubMed Abstract] Return to citation in text: [1]
231. Quinn J, Kulhanek D, Nowlin 3, Jones R, Pratico D, Rokach 3, Stackman R Chronic melatonin therapy fails to alter amyloid burden or oxidati damage in old Tg2S76 mice: implications for clinical trials. Brain Res 2005, 1037:209-213. [PubMed Abstract] Return to citation in text: [1] [2]
232. Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka-Ikeda Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y, Ikeda S, Murakami T, Abe K, Otomo E, Hirai S, Frangione B, Ghiso J, Shoji M: Soluble Aβ homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. Neurobiol Aging 2004, 25:833-841. [PubMed Abstract] Return to citation in text: [1]
233. Li XC, Wang ZF, Zhang JX, Wang Q, Wang JZ: Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005, 510:25-30. [PubMed Abstract] Return to citation in text: [1] [2]
234. Liu SJ, Wang JZ: Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002, 23:183-187. [PubMed Abstract] Return to citation in text: [1]
235. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, Wang JZ: Preventio of isoproterenol-induced tau hyperphosphorylation by melatonin the rat. Sheng Li Xue Bao 2005, 57:7-12. [PubMed Abstract] Return to citation in text: [1]
236. Skene DJ, Vivien-Roels B, Sparks DL: Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990, 528:170-174. [PubMed Abstract] Return to citation in text: [1]
237. Uchida K, Okamoto N, Ohara K, Morita Y: Daily rhythm of serum melatonin in patients with dementia of degenerative type. Brain Res 1996, 717:154-159. [PubMed Abstract] Return to citation in text: [1]
238. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF: Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4/4 genotype. J Clin Endocrinol Metab 1999, 84:323-327. [PubMed Abstract] Return to citation in text: [1] [2]
239. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M: Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999, 45:417-421. [PubMed Abstract] Return to citation in text: [1] [2]
240. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y: Daily rhythm serum melatonin levels and effect of light exposure in patients w dementia of Alzheimer's type. Biol Psychiatry 1999, 45:1646-1652. [PubMed Abstract] Return to citation in text: [1] [2]
241. Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L, Fioravanti M, Sole SB, Magri F: Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000, 35:1239-1250. (PubMed Abstract] Return to citation in text: [1]
242. Wu Y-H, Feenstra MGP, Zhou J-N, Liu R-Y, Sastre Toraño J, Van Kann HJ Fischer DF, Ravid R, Swaab DF: Molecular changes underlying reduc pineal melatonin levels in Alzheimer's disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003, 88:5898-5906. [PubMed Abstract) Return to citation in text: [1] [2]
243. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF: Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003, 35:125-130. [PubMed Abstract] Return to citation in text: [1]
244. Skene DJ, Swaab DF: Melatonin rhythmicity: effects of age and Alzheimer's disease. Exp Gerontol 2003, 38:199-206. [PubMed Abstract] Return to citation in text: [1]
245. Cardinali DP, Brusco LI, Liberczuk C, Furio AM: The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002, 23(Suppl 1):20-23. [PubMed Abstract] Return to citation in text: [1]
246. Magri F, Locatelli M, Balza G, Molla G, Cuzzoni G, Fioravanti M, Solerte SB, Ferrari E: Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Chronobiol Int 1997, 14:385-396. [PubMed Abstract] Return to citation in text: [1]
247. McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV: Treatment of sleep disturbance in Alzheimer's disease. Sleep Med Rev 2000, 4:603-628. [PubMed Abstract] Return to citation in text: [1]
248. Swaab DF, Fliers E, Partiman TS: The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 1985, 342:37-44. [PubMed Abstract] Return to citation in text: [1] [2] [3]
249. van Someren EJ: Circadian and sleep disturbances in the elderly. Exp Gerontol 2000, 35:1229-1237. [PubMed Abstract] Return to citation in text: [1] [2]
250. Swaab DF, Grundke-Iqbal I, Iqbal K, Kremer HP, Ravid R, van de Nes ]A Tau and ubiquitin in the human hypothalamus in aging and Alzheimer's disease. Brain Res 1992, 590:239-249. [PubMed Abstract] Return to citation in text: [1]
251. van de Nes JA, Kamphorst W, Ravid R, Swaab DF: The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer's disease patients. Brain 1993, 116:103-115. [PubMed Abstract] Return to citation in text: [1]
252. Giubilei F, Patacchioli FR, Antonini G, Sepe Monti M, Tisei P, Bastianello S Monnazzi P, Angelucci L: Altered circadian cortisol secretion in Alzheimer's disease: clinical and neuroradiological aspects. J Neurosci Res 2001, 66:262-265. [PubMed Abstract] Return to citation in text: [1]
253. Harper DG, Stopa EG, McKee AC, Satlin A, Harlan PC, Goldstein R, Volicer L: Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 2001, 58:353-360. [PubMed Abstract] Return to citation in text: [1]
254. Satlin A, Volicer L, Ross V, Herz L, Campbell S: Bright light treatment behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992, 149:1028-1032. [PubMed Abstract] Return to citation in text: [1] [2]
255. Campbell SS, Kripke DF, Gillin JC, Hrubovcak JC: Exposure to light in healthy elderly subjects and Alzheimer's patients. Physiol Behav 1988, 42:141-144. [PubMed Abstract] Return to citation in text: [1]
256. Pandi-Perumal SR, Seils LK, Kayumov L, Ralph MR, Lowe A, Moller H, Swaab DF: Senescence, sleep, and circadian rhythms. Ageing Res Rev 2002, 1:559-604. [PubMed Abstract] Return to citation in text: [1] (2]
257. Taylor JL, Friedman L, Sheikh J, Yesavage JA: Assessment and management of "sundowning" phenomena. Semin Clin Neuropsychiatry 1997, 2:113-122. [PubMed Abstract] Return to citation in text: [1]
258. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hori H, Takahashi K: Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994, 89:1-7. [PubMed Abstract] Return to citation in text: [1]
259. van Someren EJ, Kessler A, Mirmiran M, Swaab DF: Indirect bright ligh improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 1997, 41:955-963. [PubMed Abstract] Return to citation in text: [1]
260. Yamadera H, Ito T, Suzuki H, Asayama K, Ito R, Endo S: Effects of bright light on cognitive and sleep-wake (circadian) rhythm disturbance Alzheimer type dementia. Psychiatry Clin Neurosci 2000, 54:352-353. [PubMed Abstract] Return to citation in text: [1]
261. Brusco LI, Marquez M, Cardinali DP: Monozygotic twins with Alzheim disease treated with melatonin: Case report. J Pineal Res 1998, 25:260-263. [PubMed Abstract] Return to citation in text: [1]
262. Poeggeler B: Melatonin, aging, and age-related diseases: Perspecti for prevention, intervention and therapy. Endocrine 2005, 27:201-212. [PubMed Abstract] Return to citation in text: [1] [2]
263. Fainstein I, Bonetto A, Brusco LI, Cardinali DP: Effects of melatonin in elderly patients with sleep disturbance. Curr Ther Res 1997, 58:990-1000. Return to citation in text: [1]
264. Jean-Louis G, von Gizycki H, Zizi F: Melatonin effects on sleep, mood and cognition in elderly with mild cognitive impairment. J Pineal Res 1998, 25:177-183. [PubMed Abstract] Return to citation in text: [1]
265. Cohen-Mansfield J, Garfinkel D, Lipson S: Melatonin for treatment of sundowning in elderly patients with dementia - a preliminary study. Arch Gerontol Geriatr 2000, 31:65-76. [PubMed Abstract] Return to citation in text: [1]
266. Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R: Melatonin treatment day-night rhythm disturbances and sundowning in Alzheimer's disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004, 24:456-459. [PubMed Abstract] Return to citation in text: [1]
267. Brusco LI, Marquez M, Cardinali DP: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 2000, 21:39-42. [PubMed Abstract] Return to citation in text: [1]
268. Cardinali DP, Brusco LI, Liberczuk C, Furio AM: The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002, 23(Suppl 1):20-23. [PubMed Abstract] Return to citation in text: [1]
269. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S: Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer's type dementia. J Nippon Med Sch 2003, 70:334-341. [PubMed Abstract] Return to citation in text: [1]
270. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thai LJ, Alzheimer's Disease Cooperative Study: A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003, 26:893-901. [PubMed Abstract] Return to citation in text: [1] [2]
271. Van Coevorden A, Mockel J, Laurent E, Kerkhofs M, L'Hermite-Baleriaux M, Decoster C, Neve P, Van Cauter E: Neuroendocrine rhythms of sleep in aging men. Am J Physiol 1991, 260:E651-E661. [PubMed Abstract] Return to citation in text: [1]
272. Hairston IS, Peyron C, Denning DP, Ruby NF, Flores J, Sapolsky RM, Hell, HC, O'Hara BF: Sleep deprivation effects on growth factor expression in neonatal rats. A potential role for BDNF in the mediation of delta power. J Neurophysiol 2004, 91:1586-1595. [PubMed Abstract] Return to citation in text: [1]
273. Furio AM, Cutrera RA, Castillo Thea V, Perez Lloret S, Riccio P, Caccuri RI Brusco LL, Cardinali DP: Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with β amyloid peptide 25-35 in the suprachiasmatic nuclei. Cell Mol Neurobiol 2002, 22:699-709. [PubMed Abstract] Return to citation in text: [1]
274. Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz-Justice A, Müller-Spahn F: Cerebrovascular melatonin MT 1-receptor alterations in patients with Alzheimer's disease. Neurosci Lett 2001, 308:9-12. [PubMed Abstract] Return to citation in text: [1]
275. 2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005, 38:10-16. [PubMed Abstract] Return to citation in text: [1]
276. Golombek DA, Pévet P, Cardinali DP: Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996, 20:403-412. [PubMed Abstract] Return to citation in text: [1]
277. Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP: Melatonin and sleep in aging population. Exp Gerontol 2005, 40:911-925. [PubMed Abstract] Return to citation in text: [1]
278. Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992, 32:804-812. [PubMed Abstract] Return to citation in text: [1] [2]
279. Olanow CW: Oxidation reactions in Parkinson's disease. Neurology 1990, 40(Suppl 3):32-37. Return to citation in text: [1]
280. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increas in Parkinson's disease. J Neurochem 1989, 52:381-389. (PubMed Abstract] Return to citation in text: [1] [2]
281. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B: Oxidative DNA damage in the Parkinson brain: an apparent increase in 8-hydroxyguanine levels in the substantia nigra. J Neurochem 1997, 69:1196-1203. [PubMed Abstract] Return to citation in text: [1]
282. Perry TL, Young RS: Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986, 677:269-274. Return to citation in text: [1]
283. Chiueh CC, Burns RS, Markey SP, Jacobowitz DM, Kopin IJ: Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 1985, 36:213-218. [PubMed Abstract] Return to citation in text: [1]
284. Klaidman LK, Adams JD Jr, Leung AC, Kim SS, Cadenas E: Redox cyclin of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 1993, 15:169-179. [PubMed Abstract] Return to citation in text: [1]
285. Zhang Y, Dawson VL, Dawson TM: Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000, 7:240-250. [PubMed Abstract] Return to citation in text: [1]
286. Adams JD Jr, Chang ML, Klaidman L: Parkinson's disease - redox mechanisms. Curr Med Chem 2001, 8:809-814. [PubMed Abstract] Return to citation in text: [1]
287. Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S: 1-D administration enhances 6-hydroxydopamine generation. Brain Res 2005, 1063:180-186. [PubMed Abstract] Return to citation in text: [1]
288. Acuña-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997, 60:L23-L29. Return to citation in text: [1] [2]
289. Mayo JC, Sainz RM, Uría H, Antolin I, Estéban MM, Rodríguez C: Inhibiti of cell proliferation: a mechanism likely to mediate the prevention neuronal cell death by melatonin. J Pineal Res 1998, 25:12-18. [PubMed Abstract] Return to citation in text: [1] [2] [3]
290. Antolín I, Mayo JC, Sainz RM, del Brío M de los A, Herrera F, Martín V, Rodríguez C: Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002, 943:163-173. [PubMed Abstract] Return to citation in text: [1] [2]
291. Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P: Melato protects against 6-OHDA-induced neurotoxictiy in rats: a role for mitochondrial complex I activity. FASEB J 2001, 15:164-170. [PubMed Abstract] Return to citation in text: [1]
292. Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989, 26:719-723. [PubMed Abstract] Return to citation in text: [1]
293. Schapira AH: Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1998, 1366:225-233. [PubMed Abstract] Return to citation in text: [1]
294. Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Coope IM: Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998, 44:S89-S98. [PubMed Abstract] Return to citation in text: [1]
295. Hanagasi HA, Ayribas D, Baysal K, Emre M: Mitochondrial complex I, II/ III, and IV activities in familial and sporadic Parkinson's disea Int J Neurosci 2005, 115:479-493. [PubMed Abstract] Return to citation in text: [1]
296. +-induced mitochondrial DNA oxidative damage in vivo and in vitro. J Pineal Res 2005, 39:34-42. [PubMed Abstract] Return to citation in text: [1]
297. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I: The neuronal cytoskeleton as a potential therapeutic target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004, 3:515-533. [PubMed Abstract Return to citation in text: [1]
298. Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, Camins A, Pallas M: Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 2006, 40:251-258. [PubMed Abstract] Return to citation in text: [1] [2]
299. Monaco EA 3rd: Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr Alzheimer Res 2004, 1:33-38. [PubMed Abstract] Return to citation in text: [1]
300. Rademakers R, Sleegers K, Theuns J, Van den Broeck M, Bel Kacem S, Nilsson L-G, Adolfsson R, van Duijn CM, Van Broeckhoven C, Cruts M: Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease. Neurobiol Aging 2005, 26:1145-1151. [PubMed Abstract] Return to citation in text: [1]
301. Giese KP, Ris L, Plattner F: Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease? Neuroreport 2005, 16:1725-1730. [PubMed Abstract] Return to citation in text: [1]
302. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005, 25:8843-8853. [PubMed Abstract] Return to citation in text: [1]
303. Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J: Cyclin-dependent kinase 5 is required for associative learning. J Neurosci 2002, 22:3700-3707. [PubMed Abstract] Return to citation in text: [1]
304. Fischer A, Sananbenesi F, Spiess J, Radulovic J: Cdk5 in the adult nondemented brain. Curr Drug Targets CNS Neurol Disord 2003, 2:375-381. [PubMed Abstract Return to citation in text: [1]
305. Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai L-H: Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 2005, 48:825-838. [PubMed Abstract] Return to citation in text: [1] [2]
306. LaFerla FM, Kitazawa M: Antipodal effects of p25 on synaptic plastic learning, and memory - too much of a good thing is bad. Neuron 2005, 48:711-712. [PubMed Abstract] Return to citation in text: [1]
307. Iacovitti L, Stull ND, Johnston K: Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res 1997, 768:317-326. [PubMed Abstract] Return to citation in text: [1]
308. Willis GL, Armstrong SM: A therapeutic role for melatonin antagonis in experimental models of Parkinson's disease. Physiol Behav 1999, 66:785-795. [PubMed Abstract] Return to citation in text: [1] [2]
309. Willis GL, Robertson AD: Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol Biochem Behav 2004, 79:413-429. [PubMed Abstract] Return to citation in text: [1] [2]
310. Willis GL, Robertson AD: Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML Pharmacol Biochem Behav 2005, 80:9-26. [PubMed Abstract] Return to citation in text: [1] [2]
311. Fertl E, Auff E, Doppelbauer A, Waldhauser F: Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991, 3:41-47. [PubMed Abstract Return to citation in text: [1]
312. Fertl E, Auff E, Doppelbauer A, Waldhauser F: Circadian secretion pattern of melatonin in de novo Parkinson's patients: evidence for phase-shifting properties of L-dopa. J Neural Transm Park Dis Dement Sect 1993, 5:227-234. [PubMed Abstract] Return to citation in text: [1]
313. Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, Destée A: Study of circadian melatonin secretion pattern at different stages Parkinson's disease. Clin Neuropharmacol 2003, 26:65-72. [PubMed Abstract] Return to citation in text: [1] [2] [3]
314. Escames G, Acuña-Castroviejo, Vives F: Melatonin-dopamine interaction in the striatal projection area of sensorilmotor cortex in the rat. Neuroreport 1996, 7:597-600. [PubMed Abstract] Return to citation in text: [1]
315. Catala MD, Canete-Nicolas C, Iradi A, Tarazona PJ, Tormos JM, Pascual-Leone A: Melatonin levels in Parkinson's disease: drug therapy vei electrical stimulation of the internal globus pallidus. Exp Gerontol 1997, 32:553-558. [PubMed Abstract] Return to citation in text: [1]
316. Olanow CW, Brin MF, Obeso JA: The role of deep brain stimulation as a surgical treatment for Parkinson's disease. Neurology 2000, 55:S60-S66. [PubMed Abstract] Return to citation in text: [1]
317. Haimov I, Lavie P: Potential of melatonin replacement therapy in o patients with sleep disorders. Drugs Aging 1995, 7:75-78. [PubMed Abstract] Return to citation in text: [1]
318. Hughes RJ, Sack RL, Lewy AJ: The role of melatonin and circadian phase in age-related sleep maintenance insomnia: assessment in clinical trial of melatonin replacement. Sleep 1998, 21:52-66. [PubMed Abstract] Return to citation in text: [1]
319. Dowling GA, Mastick J, Aminoff MJ: Melatonin for sleep disturbances Parkinson's disease: a pilot study. Sleep Res Online 2003, 5:99-103. Return to citation in text: [1]
320. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ: Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005, 6:459-466. [PubMed Abstract] Return to citation in text: (1] [2]
321. Hilditch -Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME: Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000, 9:2789-2797. [PubMed Abstract] Return to citation in text: [1]
322. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH: Biochemical abnormalities and excitotoxicity in Huntington's dise brain. Ann Neurol 1999, 45:25-32. [PubMed Abstract] Return to citation in text: [1]
323. Schapira AH: Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreichs's ataxia. Biochim Biophys Acta 1999, 1410:159-170. [PubMed Abstract] Return to citation in text: [1]
324. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT: Early mitochondrial calcium defects in Huntington' disease are direct effects of polyglutamines. Nat Neurosci 2002, 5:731-736. [PubMed Abstract] Return to citation in text: [1]
325. 2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 2003, 410:1-6. [PubMed Abstract] Return to citation in text: [1]
326. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA: Increased sensitivity of N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860. [PubMed Abstract] Return to citation in text: [1]
327. Ellerby LM: Hunting for excitement: NMDA receptors in Huntington disease. Neuron 2002, 33:841-842. [PubMed Abstract] Return to citation in text: [1]
328. Whetsell WO Jr, Schwarcz R: Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotrophic cultures of rat corticostriatal system. Neurosci Lett 1989, 97:271-275. [PubMed Abstract] Return to citation in text: [1]
329. Reynolds NC Jr, Lin W, Meyer Cameron C, Roerig DL: Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. Brain Res 1997, 778:140-149. [PubMed Abstract] Return to citation in text: [1] [2]
330. 1H NMR spectroscopy. J Neurosci Res 2001, 66:891-898. [PubMed Abstract] Return to citation in text: [1]
331. Fusco FR, Zuccato C, Tartari M, Martorana A, De March Z, Giampa C, Cattaneo E, Bernardi G: Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur J Neurosci 2003, 18:1093-1102. [PubMed Abstract] Return to citation in text: [1]
332. Goda K, Kishimoto R, Shimizu S, Hamane Y, Ueda M: Quinolinic acid and active oxygens. Possible contribution of active oxygens during ce death in the brain. Adv Exp Med Biol 1996, 398:247-254. [PubMed Abstract] Return to citation in text: [1]
333. Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Stee CJ, Low WC: A bile acid protects against motor and cognitive deficts and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol 2001, 171:351-360. [PubMed Abstract] Return to citation in text: [1]
334. Antonawich FJ, Fiore-Marasa SM, Parker CP: Modulation of apoptotic regulatory proteins and early activation of cytochrome C followin, systemic 3-nitropropionic acid administration. Brain Res Bull 2002, 57:647-649. [PubMed Abstract] Return to citation in text: [1]
335. Southgate G, Daya S: Melatonin reduces quinolinic acid-induced lip peroxidation in rat brain homogenate. Metab Brain Dis 1999, 14:165-171. [PubMed Abstract] Return to citation in text: [1]
336. Southgate GS, Daya S, Potgieter B: Melatonin plays a protective role quinolinic acid-induced neurotoxicity in the rat hippocampus. J Chem Neuroanat 1998, 14:151-156. [PubMed Abstract] Return to citation in text: [1]
337. Behan WM, McDonald M, Darlington LG, Stone TW: Oxidative stress as mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999, 128:1754-1760. [PubMed Abstract] Return to citation in text: [1]
338. Cabrera J, Reiter RJ, Tan D-X, Qi W, Sainz RM, Mayo JC, Garcia JJ, Kim S El-Sokkary G: Melatonin reduces oxidative neurotoxicity due to quinolinic acid: in vitro and in vivo findings. Neuropharmacology 2000, 39:507-514. [PubMed Abstract] Return to citation in text: [1]
339. Vega-Naredo I, Poeggeler B, Sierra-Sánchez V, Caballero B, Tomás-Zapil C, Álvarez-García O, Tolivia D, Rodríguez-Colunga MJ, Coto-Montes A: Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture. J Pineal Res 2005, 39:266-275. [PubMed Abstract] Return to citation in text: [1]
340. Túnez I, Montilla P, Muñoz M del C, Feljóo M, Salcedo M: Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 2004, 37:252-256. [PubMed Abstract] Return to citation in text: [1]
341. Jacob S, Poeggeler B, Weishaupt JH, Sirén A-L, Hardeland R, Bähr M, Ehrenreich H: Melatonin as a candidate compound for neuroproted in amyotrophic lateral sclerosis (ALS): High tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 2002, 33:186-187. [PubMed Abstract] Return to citation in text: [1]
342. Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huether G, Schneider A, Bach A, Sirén A-L, Hardeland R, Bähr M, Nave K-A, Ehrenreich H: Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. 2002. manuscript submitted Return to citation in text: [1]
343. Sharman EH, Sharman KG, Ge YW, Lahiri DK, Bondy SC: Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. J Pineal Res 2004, 36:165-170. [PubMed Abstract] Return to citation in text: [1]